Genomic Valley Biotech
- Market cap
- ₹ 12 Cr.
- P/E
- 1,332.7x
- P/B
- 2.79x
- 52-week range
- 20.1 – 43.63
- ROE
- 1%
- ROCE
- 1%
- Dividend yield
- 0%
- Debt / equity
- 0
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Biotechnology
- Listed on
- BSE
About
Genomic Valley Biotech Limited is an India-based company, which is engaged in the business of consultancy, and trading in agricultural and horticultural products. The Company is providing consultancy on high-tech cultivation through environment-controlled poly houses, NFT & DFT and others, and organic farming - open field cultivation using bio-fertilizer. It is involved in commercial greenhouse cultivation of crops like seed less cucumber, capsicum and others. It is involved in commercial floriculture activities with flowers like Gerbera, Chrysanthemum and others. It extends turnkey support to farmers and entrepreneurs in setting up of greenhouses and polyhouses. It is acting as authorized dealer of Netafim Irrigations India Pvt Ltd, an Israeli company specialized in marketing and selling of its irrigation related products. It is involved in the manufacturing and marketing of bio-fertilizer commercially to promote organic farming. It has a commercial plant tissue culture laboratory.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Biotechnology: 6 companies →Genomic Valley Biotech against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)1,332.7 against a typical 64.5: pricier than most peers (1st = cheapest).6th of 6
- Sales growth−55.6% against a typical +2.2% from a year earlier.5th of 5
- Profit growth−50% against a typical −50% from a year earlier.3rd of 5
- Share price, 3 months+53.1% against a typical −13.2%.1st of 5
- Size₹ 11.5 Cr. market value against a typical ₹ 82.4 Cr. (1st = largest).6th of 6
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Profit | 0 | 0 | −0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| OPM % | 28.6% | 50% | — | 81.3% | 66.7% | 72.7% | 0% | 33.3% | 0% | 20% | 0% | 50% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | 0 | −0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | — | 0% | — | 0% | — | 0% |
| Net Profit | 0 | 0 | −0 | 0 | 0 | 0 | −0 | 0 | 0 | 0 | −0 | 0 |
| EPS in Rs | 0.07 | 0.07 | −0.13 | 0.43 | 0.49 | 0.52 | −0.26 | 0.07 | 0 | 0.03 | −0.03 | 0.03 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 9%
- 5 Years
- 5%
- 3 Years
- −54%
- TTM
- −72%
- 10 Years
- 8%
- 5 Years
- 15%
- 3 Years
- −68%
- TTM
- −96%
- 10 Years
- —
- 5 Years
- 6%
- 3 Years
- 11%
- TTM
- —
- 10 Years
- 2%
- 5 Years
- 5%
- 3 Years
- 4%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Genomic Valley Biotech | ₹ 43.63 | ₹ 12 Cr. | 1,332.7x | 2.8x | 1% | — |
| Delhivery | ₹ 370.00 | ₹ 27,724 Cr. | 207.5x | 3.2x | — | 0.8% |
| Urban Company | ₹ 132.65 | ₹ 20,457 Cr. | — | 11.2x | — | −19.5% |
| Indegene | ₹ 570.00 | ₹ 13,763 Cr. | 33.8x | 4.5x | — | 10.5% |
| BLS International Services | ₹ 208.70 | ₹ 8,593 Cr. | 13x | 3.6x | — | 23.4% |
| Axiscades Technologies | ₹ 1,915.00 | ₹ 8,154 Cr. | 106x | 11.9x | — | 4% |
Management
- Yogesh Kumar Agrawal
- Executive Chairman of the Board, Managing Director, Chief Financial Officer
- Aditya Aditya
- Company Secretary, Compliance Officer
Prices are delayed and for information only. Nothing on this page is investment advice.